Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

Now, after setting an innovative medicines sales record in the year’s second quarter, it appears J&J’s confidence was well placed.

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

Guselkumab improves scalp psoriasis and quality of life in patients with skin of color.

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients with active psoriatic arthritis, according to data presented at the ...

Guselkumab significantly improves psoriasis severity and quality of life compared with placebo in patients with skin of color.

Guselkumab European Commission approval in Crohn's disease builds upon recent ulcerative colitis approval,4 marking the fourth indication for this dual-acting IL-23 inhibitor in the European Union.2 ...

The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic ...